Research Brief: WU-CART-007 Receives FDA Breakthrough Therapy Designation for Relapsed T-Cell Leukemia and Lymphoma
Research Brief: WU-CART-007 Receives FDA Breakthrough Therapy Designation for Relapsed T-Cell Leukemia and Lymphoma
EllenRx Research Brief | April 2026 | Audience: Patients seeking clinical trial access
Abstract
On January 21, 2026, the FDA granted Breakthrough Therapy designation to soficabtagene geleucel (sofi-cel; WU-CART-007), an investigational allogeneic CAR-T cell therapy developed by Wugen Inc., for relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in pediatric and adult patients.¹ The therapy is manufactured from donor cells in advance rather than from a patient's own cells, a distinction with direct implications for how quickly treatment can begin. A pivotal Phase 2 clinical trial, T-RRex (NCT06514794), is actively enrolling.² This brief explains the science, what the FDA designation means in practice, how to explore trial access, and what the current coverage landscape looks like for patients who need cell therapies today.
What T-Cell ALL and T-Cell Lymphoblastic Lymphoma Are
T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma are rare, aggressive blood cancers arising from immature T-cells in the bone marrow or lymphatic system. They are most common in children, adolescents, and young adults, though they occur at any age. Together, T-ALL and T-LBL account for roughly 25% of all acute lymphoblastic leukemia cases.³
At initial diagnosis, intensive chemotherapy produces meaningful responses. The problem is relapse. When T-ALL or T-LBL returns after treatment, or fails to respond initially, outcomes become significantly harder to achieve. Standard salvage regimens often produce only temporary remissions, and the window for durable response narrows with each subsequent treatment cycle. For patients in this situation, access to investigational therapies becomes urgent.
What CAR-T Therapy Is, in Plain Language
CAR-T stands for chimeric antigen receptor T-cell therapy. T-cells, which normally identify and destroy abnormal cells, can be engineered to target a specific protein on cancer cell surfaces.
In CAR-T treatment, T-cells are collected, engineered in a laboratory to carry a receptor that recognizes a target protein on cancer cells, expanded into the millions, and infused back into the patient. Those modified cells then seek out and attack cells displaying that protein.
WU-CART-007 targets CD7, a protein found on T-cell malignancies.¹ Because the engineered cells themselves carry CD7 and would otherwise attack each other, Wugen uses CRISPR gene editing to remove CD7 from the manufactured cells before infusion.⁴
What Allogeneic Means, and Why It Matters for Patients
Most currently approved CAR-T therapies are autologous: made from a patient's own cells. That process requires collecting cells from the patient, shipping them to a manufacturing facility, engineering and quality-testing them, and shipping them back, a sequence that typically runs three to six weeks. For a patient with rapidly progressing disease, that timeline can determine whether treatment remains an option at all.
WU-CART-007 is allogeneic, manufactured from donor cells in large batches in advance. This off-the-shelf model means the therapy can potentially be available within days of a treatment decision rather than weeks.¹ For pediatric and young adult patients in relapse, whose disease can accelerate quickly, the timing difference is clinically consequential. An off-the-shelf model may also reduce manufacturing costs over time, though commercial pricing decisions have not yet been made.
What FDA Breakthrough Therapy Designation Means
Breakthrough Therapy designation is an FDA program to accelerate development and review of medicines for serious or life-threatening conditions when preliminary clinical evidence suggests the drug may substantially improve upon existing therapy.⁵ It provides more intensive FDA guidance during development, commitment from senior FDA leadership, and closer collaboration to optimize clinical trial design.
It is not approval. WU-CART-007 is not approved for any use outside of clinical trials. No patient can receive it today except through a clinical study. The designation signals that the FDA sees sufficient early promise to prioritize the development program; it is not a statement that the therapy meets the safety and efficacy standards required for commercial approval.
Wugen has received a substantial stack of FDA designations for sofi-cel: Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, Rare Pediatric Disease, and now Breakthrough Therapy.¹ Each provides a different regulatory benefit. Collectively, they reflect that regulators see this program as addressing a genuine unmet need.
How to Access WU-CART-007 Now: The T-RRex Trial
The pivotal Phase 2 trial evaluating WU-CART-007, T-RRex, is registered at ClinicalTrials.gov as NCT06514794 and is currently recruiting pediatric and adult patients with relapsed or refractory T-ALL or T-LBL.² Wugen is also initiating an exploratory cohort for patients with minimal residual disease.¹
Participating sites include major academic cancer centers; MD Anderson Cancer Center and Cincinnati Children's Hospital Medical Center are among the institutions running the trial.² In August 2025, Wugen secured $115 million to advance T-RRex toward a potential approval submission, which supports continued enrollment and site expansion.⁷
If you or someone in your family has a diagnosis of relapsed or refractory T-ALL or T-LBL, contact a trial site directly or ask your oncologist to evaluate eligibility. Eligibility criteria for CAR-T trials typically include prior treatment history, performance status, and organ function thresholds. Your oncologist can assess whether the trial's inclusion criteria fit your specific situation and whether a referral to a participating center makes sense.
The Coverage Reality for Approved CAR-T Therapies Today
Four CAR-T therapies are currently FDA-approved for hematological cancers: tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and ciltacabtagene autoleucel (Carvykti). None are approved for T-cell ALL or T-LBL. They are relevant here because they illustrate the coverage landscape any patient will navigate once a new cell therapy reaches approval.
Medicare covers FDA-approved CAR-T therapies under National Coverage Determination 110.24, effective since August 2019, for patients treated at approved clinical sites.⁶ Medicare also covers routine costs in qualifying clinical trials under NCD 310.1, meaning costs related to standard care and monitoring during trial participation may be covered even when the experimental therapy itself is not billed to Medicare.⁶
For commercial insurance, coverage of approved CAR-T therapies exists but is not universal. Insurers may require prior authorization, limit approval to specific diagnoses, or require treatment at an in-network specialized center. Denials typically rest on arguments about medical necessity, out-of-network facility designation, or an indication that does not match the approved label.
If you are navigating a denial for any CAR-T therapy today, the most effective appeals include documentation from your treating oncologist explaining why the therapy is medically necessary, clinical literature supporting the use for your specific diagnosis, and details about the treating center's qualifications and certification status.
What to Do Now
If you or someone in your family has been diagnosed with T-ALL or T-LBL and has relapsed after treatment:
WU-CART-007 is not yet approved. For patients with relapsed T-cell leukemia or lymphoma who have exhausted standard options, the clinical trial is the access point available today.